Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $5.95 in the last session, down -5.71% from day before closing price of $6.31. In other words, the price has decreased by -$5.71 from its previous closing price. On the day, 23.69 million shares were traded. RXRX stock price reached its highest trading level at $6.2799 during the session, while it also had its lowest trading level at $5.86.
Ratios:
We take a closer look at RXRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.11 and its Current Ratio is at 4.11. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
On May 22, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.Needham initiated its Buy rating on March 16, 2023, with a $17 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 27 ’25 when Gibson Christopher sold 138,574 shares for $6.04 per share. The transaction valued at 836,987 led to the insider holds 1,117,450 shares of the business.
Gibson Christopher bought 138,574 shares of RXRX for $836,987 on Mar 27 ’25. On Mar 05 ’25, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 20,000 shares for $6.58 each. As a result, the insider received 131,600 and left with 1,256,024 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2579782912 and an Enterprise Value of 2013610112. For the stock, the TTM Price-to-Sale (P/S) ratio is 43.00 while its Price-to-Book (P/B) ratio in mrq is 2.59. Its current Enterprise Value per Revenue stands at 33.678 whereas that against EBITDA is -3.831.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.95, which has changed by -0.27439022 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is 15.23%, while the 200-Day Moving Average is calculated to be -4.75%.
Shares Statistics:
According to the various share statistics, RXRX traded on average about 28.19M shares per day over the past 3-months and 35516570 shares per day over the past 10 days. A total of 399.15M shares are outstanding, with a floating share count of 330.56M. Insiders hold about 23.50% of the company’s shares, while institutions hold 56.82% stake in the company. Shares short for RXRX as of 1752537600 were 115527481 with a Short Ratio of 4.10, compared to 1749772800 on 120075634. Therefore, it implies a Short% of Shares Outstanding of 115527481 and a Short% of Float of 28.599999999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
